Reuters logo
3 months ago
BRIEF-Incyte Q1 loss per share $0.96
May 4, 2017 / 11:44 AM / 3 months ago

BRIEF-Incyte Q1 loss per share $0.96

1 Min Read

May 4 (Reuters) - Incyte Corp

* Incyte reports 2017 first-quarter financial results and updates on key clinical programs

* Q1 revenue $384 million versus i/b/e/s view $360.1 million

* Q1 loss per share $0.96

* Q1 earnings per share view $-1.00 -- Thomson Reuters I/B/E/S

* Incyte corp - Olumiant(®) (baricitinib) approved by european commission for treatment of moderate to severe active rheumatoid arthritis

* Incyte corp - incyte and lilly disagree with fda's complete response letter for baricitinib

* Incyte corp - expects that lilly will now engage with fda to discuss agency's concerns and determine a potential path forward

* Incyte corp - novartis anticipates submitting an nda for capmatinib, incyte's potent and selective c-met inhibitor, in 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below